Skip to main content

Table 2 Descriptive statistics for LVEF by treatmenta

From: Cardiac safety of afatinib: a review of data from clinical trials

LL3 Afatinib (40 mg/day) n = 229 Chemotherapy n = 111
 Baseline LVEF, mean (SD) 66.0 (6.90) 66.60 (8.0)
 Minimum LVEF during treatment, mean (SD) 62.63 (6.33) 68.87 (10.59)
 % change from baseline to minimum, mean (SD) −4.90 (9.95) −1.06 (15.30)
 Last LVEF during treatment, mean (SD) 67.30 (7.10) 68.90 (10.60)
 % change from baseline to last, mean (SD) 2.17 (11.41) −1.06 (15.30)
LL1 Afatinib (50 mg/day) n = 390 Placebo n = 195
 Baseline LVEF, mean (SD) 64.90 (6.60) 63.90 (7.70)
 Minimum LVEF during treatment, mean (SD) 62.35 (6.57) 63.73 (7.87)
 % change from baseline to minimum, mean (SD) −3.41 (9.14) −0.88 (12.13)
 Last LVEF during treatment, mean (SD) 64.20 (7.0) 64.40 (7.70)
 % change from baseline to last, mean (SD) −0.39 (10.40) 0.27 (12.62)
  1. LVEF left ventricular ejection fraction, LL3 LUX-Lung 3, SD standard deviation, LL1 LUX-Lung 1, ECHO echocardiogram
  2. aIn LL3, 208 patients in the afatinib arm and 15 patients in the chemotherapy arm had a follow-up ECHO; in LL1, 304 patients in the afatinib arm and 122 patients in the placebo arm had a follow-up ECHO